Thursday. France has fined Novo Nordisk and Eli Lilly for obesity "awareness" campaigns that the regulator decided were really advertisements.
The fines are small, and that is the whole story: the question is not whether the two got caught but whether a penalty this size changes anything. India, further along the same road, offers a preview.
France Writes The Ticket
In May, the ANSM, France's medicines regulator, fined the two companies for obesity awareness campaigns it judged misleading and aimed straight at patients. Novo drew more than €1.78 million; Lilly, €108,766 over a campaign titled "obesity is a sick thing" that, the regulator said, cast its tirzepatide drug as the only fix by leaving out every other way to lose weight. Both said the campaigns were educational and pointed people to their doctors. That runs into the first rule of European drug marketing: you may not advertise a prescription medicine to consumers.
What makes the case matter is not just the money but also what counted as an ad. The campaigns never named the drugs by brand. The ANSM decided the public was "highly likely" to connect obesity messaging from companies that sell obesity drugs to the drugs themselves, regardless of their own weight, and that was enough. Barbara Mintzes, a professor of evidence-based pharmaceutical policy at the University of Sydney, has watched this style for years; what is new, she said, is that "the regulator has responded to these promotional campaigns." Unbranded campaigns usually slip past drug-advertising rules precisely because they omit the product. Treating one as a promotion anyway moves the line.
Now the money, because the money is a big part of the argument. Set the fines beside the sales, and they read less like deterrence than a toll. The French code caps the penalty at €1 million per drug and scales it to what that drug earned in the country the year before, so Novo's Saxenda drew the ceiling against more than €14 million of French sales in a single year. A fine is a cost of doing business when a medicine makes this much. Jérôme Sclafer, an editor at the independent French medical journal Prescrire, said the quiet part out loud: the ANSM is slow to act, so "it can still be worth the risk of a fine." France could, in principle, cool demand by rationing reimbursement to the sickest patients; it fined the advertiser instead, which is easier and more popular than telling doctors to prescribe less.